Brendan P. Eckelman
2022
In 2022, Brendan P. Eckelman earned a total compensation of $704K as Chief Scientific Officer at Inhibrx, a 58% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $213,750 |
|---|---|
| Salary | $475,000 |
| Other | $15,250 |
| Total | $704,000 |
Eckelman received $475K in salary, accounting for 67% of the total pay in 2022.
Eckelman also received $213.8K in non-equity incentive plan and $15.3K in other compensation.
Rankings
In 2022, Brendan P. Eckelman's compensation ranked 3,770th out of 5,760 executives tracked by ExecPay. In other words, Eckelman earned more than 34.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,770 out of 5,760 | 35th |
Division Manufacturing | 2,134 out of 3,136 | 32nd |
Major group Chemicals And Allied Products | 1,033 out of 1,422 | 27th |
Industry group Drugs | 969 out of 1,323 | 27th |
Industry Biological Products, Except Diagnostic Substances | 227 out of 291 | 22nd |
Source: SEC filing on April 13, 2023.
Eckelman's colleagues
We found two more compensation records of executives who worked with Brendan P. Eckelman at Inhibrx in 2022.